文献速递皮肤肿瘤

N6-甲基腺苷RNA甲基化与黑色素瘤免疫微环境及免疫治疗反应相关

N6-methyladenosine RNA Methylation Correlates with Immune Microenvironment and Immunotherapy Response of Melanoma.
PubMed 文献 · J Invest Dermatol · 2023-02-24

在8个独立黑色素瘤队列(1564例患者)中,21个m6A基因特征的修饰模式与肿瘤微环境免疫细胞浸润系统相关;低m6Ascore者5年生存率61.1%、高m6Ascore者52.2%,低m6Ascore与更敏感的anti-PD-1和anti-CTLA4治疗反应相关。

要点

  • 黑色素瘤患者中观察到两种m6A修饰模式,分为高和低m6Ascore,与生存和治疗反应相关。
  • 低m6Ascore特征为免疫炎症表型,5年生存率61.1%;高m6Ascore特征为免疫排斥表型,5年生存率52.2%。
  • 在队列GSE63557中,低m6Ascore患者90%对治疗有反应,高m6Ascore患者10%无反应。

核心结论

  • m6Ascore与肿瘤免疫逃逸的重要方面相关,可作为个性化医学工具指导黑色素瘤患者的免疫治疗。

研究设计与样本

  • 研究纳入8个独立黑色素瘤队列,共1564例患者,系统分析21个m6A基因特征的修饰模式与免疫细胞浸润的相关性。
  • 采用主成分分析方法量化每位患者的m6A修饰模式,得出反映m6A RNA修饰丰度的m6Ascore。

主要发现

  • 黑色素瘤患者中观察到两种不同的m6A修饰模式,分为高和低m6Ascore,与生存和治疗反应相关。
  • 低m6Ascore特征为免疫炎症表型,5年生存率为61.1%;高m6Ascore特征为免疫排斥表型,5年生存率为52.2%。
  • 在队列GSE63557中,低m6Ascore与更敏感的anti-PD-1和anti-CTLA4治疗反应相关,低m6Ascore患者90%有反应,高m6Ascore患者10%无反应。
  • 在单细胞和空间转录组分辨率下,m6Ascore反映黑色素瘤恶性进展、免疫耗竭和对免疫检查点阻断治疗的抵抗。

关键数值与推荐

  • 低m6Ascore:免疫炎症表型,5年生存率61.1%。
  • 高m6Ascore:免疫排斥表型,5年生存率52.2%。
  • 队列GSE63557中,低m6Ascore患者90%对anti-PD-1和anti-CTLA4治疗有反应,高m6Ascore患者10%无反应。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RNA methylation normally inhibits the self-recognition and immunogenicity of RNA. As such, it is likely an important inhibitor of cancer immune recognition in the tumor microenvironment, but how N6-methyladenosine (m6A) affects prognosis and treatment response remains unknown. In eight independent melanoma cohorts (1,564 patients), the modification patterns of 21 m6A gene signatures were systematically correlated with the immune cell infiltration of melanoma tumor microenvironment. m6A modification patterns for each patient were quantified using the principal component analysis method, yielding an m6Ascore that reflects the abundance of m6A RNA modifications. Two different m6A modification patterns were observed in patients with melanoma, separated into high and low m6Ascores that correlated with survival and treatment response. Low m6Ascores were characterized by an immune-inflamed phenotype, with 61.1% 5-year survival. High m6Ascores were characterized by an immune-excluded phenotype, with 52.2% 5-year survival. Importantly, lower m6Ascores correlated with more sensitive anti-PD-1 and anti-CTLA4 treatment responses, with 90% of patients with low m6Ascore responding, whereas 10% of those with high m6Ascore nonresponding (in cohort GSE63557). At single-cell and spatial transcriptome resolution, m6Ascore reflects melanoma malignant progression, immune exhaustion, and resistance to immune checkpoint blockade therapy. Hence, the m6Ascore correlates to an important facet of tumor immune escape as a tool for personalized medicine to guide immunotherapy in patients with melanoma.

来源:J Invest Dermatol,查看原文。版权归原作者所有。

引用

  1. Wang G, Zeng D, Sweren E, et al. N6-methyladenosine RNA Methylation Correlates with Immune Microenvironment and Immunotherapy Response of Melanoma. J Invest Dermatol. 2023. PMID: 36842525. doi:10.1016/j.jid.2023.01.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。